ZA969722B - Pharmaceutical formulations. - Google Patents
Pharmaceutical formulations.Info
- Publication number
- ZA969722B ZA969722B ZA9609722A ZA969722A ZA969722B ZA 969722 B ZA969722 B ZA 969722B ZA 9609722 A ZA9609722 A ZA 9609722A ZA 969722 A ZA969722 A ZA 969722A ZA 969722 B ZA969722 B ZA 969722B
- Authority
- ZA
- South Africa
- Prior art keywords
- pharmaceutical formulations
- formulations
- pharmaceutical
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
- A61K9/2846—Poly(meth)acrylates
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB9523752.5A GB9523752D0 (en) | 1995-11-21 | 1995-11-21 | Pharmaceutical formulations |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA969722B true ZA969722B (en) | 1998-05-20 |
Family
ID=10784188
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA9609722A ZA969722B (en) | 1995-11-21 | 1996-11-20 | Pharmaceutical formulations. |
Country Status (29)
| Country | Link |
|---|---|
| EP (1) | EP0862437A1 (en) |
| JP (1) | JPH10513481A (en) |
| KR (1) | KR19990071505A (en) |
| CN (1) | CN1215993A (en) |
| AP (1) | AP718A (en) |
| AR (1) | AR004335A1 (en) |
| AU (1) | AU709560B2 (en) |
| BG (1) | BG102438A (en) |
| BR (1) | BR9611626A (en) |
| CA (1) | CA2232715A1 (en) |
| CO (1) | CO4480020A1 (en) |
| CZ (1) | CZ155498A3 (en) |
| GB (1) | GB9523752D0 (en) |
| HR (1) | HRP960554A2 (en) |
| HU (1) | HUP9903734A3 (en) |
| IS (1) | IS4706A (en) |
| MA (1) | MA26410A1 (en) |
| MX (1) | MX9804008A (en) |
| NO (1) | NO982302L (en) |
| NZ (1) | NZ322053A (en) |
| OA (1) | OA10687A (en) |
| PE (1) | PE22898A1 (en) |
| PL (1) | PL326981A1 (en) |
| SK (1) | SK63098A3 (en) |
| TN (1) | TNSN96141A1 (en) |
| TR (1) | TR199800902T2 (en) |
| WO (1) | WO1997018814A1 (en) |
| YU (1) | YU62096A (en) |
| ZA (1) | ZA969722B (en) |
Families Citing this family (59)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2314993A1 (en) * | 1997-12-16 | 1999-06-24 | Pfizer Products Inc. | Combination effective for the treatment of impotence |
| AP1224A (en) | 1998-03-19 | 2003-11-14 | Bristol Myers Squibb Co | Biphasic controlled release delivery system for high solubility pharmaceuticals and method. |
| GT199900061A (en) * | 1998-05-15 | 2000-10-14 | Pfizer | PHARMACEUTICAL FORMULATIONS. |
| EP0974343B1 (en) * | 1998-07-22 | 2004-09-29 | Pharma Pass II LLC | Process for manufacturing a solid metoprolol composition |
| EP0987020A1 (en) * | 1998-09-04 | 2000-03-22 | Pharma Pass LLC | Metoprolol composition and processes for manufacturing the same |
| CO5140079A1 (en) * | 1998-10-14 | 2002-03-22 | Novartis Ag | PHARMACEUTICAL COMPOSITION OF SUSTAINED LIBERATION AND METHOD TO RELEASE A PHARMACEUTICALLY ACTIVE AGENT FROM SUSTAINED LIBERATION AND METHOD TO RELEASE A PHARMACEUTICALLY ACTIVE AGENT |
| UA67802C2 (en) * | 1998-10-23 | 2004-07-15 | Пфайзер Рісьоч Енд Дівелепмент Компані, Н.В./С.А. | CONTROLLED-RELEASE FORMULATIONS FOR ORAL ADMINISTRATION CONTAINING cGMP PDE-5 INHIBITOR (VARIANTS), METHOD FOR ITS PREPARATION AND METHOD FOR TREATING ERECTILE DYSFUNCTION |
| US20030059467A1 (en) * | 2001-09-14 | 2003-03-27 | Pawan Seth | Pharmaceutical composition comprising doxasozin |
| US7612112B2 (en) | 2001-10-25 | 2009-11-03 | Depomed, Inc. | Methods of treatment using a gastric retained gabapentin dosage |
| TWI312285B (en) | 2001-10-25 | 2009-07-21 | Depomed Inc | Methods of treatment using a gastric retained gabapentin dosage |
| US6723340B2 (en) | 2001-10-25 | 2004-04-20 | Depomed, Inc. | Optimal polymer mixtures for gastric retentive tablets |
| US8329217B2 (en) | 2001-11-06 | 2012-12-11 | Osmotica Kereskedelmi Es Szolgaltato Kft | Dual controlled release dosage form |
| US7407955B2 (en) | 2002-08-21 | 2008-08-05 | Boehringer Ingelheim Pharma Gmbh & Co., Kg | 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions |
| WO2005037247A2 (en) * | 2003-10-17 | 2005-04-28 | Ranbaxy Laboratories Limited | Oral matrix formulations of doxazosin |
| WO2005107702A2 (en) * | 2004-05-11 | 2005-11-17 | Glenmark Pharmaceuticals Limited | Sustained release, mucoadhesive vaginal pharmaceutical compositions |
| KR100574554B1 (en) * | 2004-05-28 | 2006-04-27 | 한미약품 주식회사 | Sustained release composition for oral administration of niacin |
| DE102004054054A1 (en) | 2004-11-05 | 2006-05-11 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Process for preparing chiral 8- (3-amino-piperidin-1-yl) -xanthines |
| KR100679111B1 (en) * | 2004-11-20 | 2007-02-07 | 대우약품공업주식회사 | A sustained release tablet comprising doxazosin |
| EP1919460A2 (en) * | 2005-08-22 | 2008-05-14 | Novartis AG | Pharmaceutical compositions comprising a ph-dependent drug, a ph modifier and a retarding agent |
| US20090176882A1 (en) | 2008-12-09 | 2009-07-09 | Depomed, Inc. | Gastric retentive gabapentin dosage forms and methods for using same |
| EP2359830B1 (en) | 2006-04-26 | 2012-09-19 | Supernus Pharmaceuticals, Inc. | Controlled released preparations of oxcarbazepine having sigmoidal release profile |
| EP1852108A1 (en) | 2006-05-04 | 2007-11-07 | Boehringer Ingelheim Pharma GmbH & Co.KG | DPP IV inhibitor formulations |
| PE20080251A1 (en) | 2006-05-04 | 2008-04-25 | Boehringer Ingelheim Int | USES OF DPP IV INHIBITORS |
| MX2008014024A (en) | 2006-05-04 | 2008-11-14 | Boehringer Ingelheim Int | Polymorphs. |
| CN100396282C (en) * | 2006-07-25 | 2008-06-25 | 山东省医药工业研究所 | Slow released doxazosin mesilate capsule and its prepn process |
| SA07280459B1 (en) | 2006-08-25 | 2011-07-20 | بيورديو فارما إل. بي. | Tamper Resistant Oral Pharmaceutical Dosage Forms Comprising an Opioid Analgesic |
| US8372432B2 (en) | 2008-03-11 | 2013-02-12 | Depomed, Inc. | Gastric retentive extended-release dosage forms comprising combinations of a non-opioid analgesic and an opioid analgesic |
| AU2009223061B2 (en) | 2008-03-11 | 2014-10-09 | Depomed Inc. | Gastric retentive extended-release dosage forms comprising combinations of a non-opioid analgesic and an opioid analgesic |
| PE20091730A1 (en) | 2008-04-03 | 2009-12-10 | Boehringer Ingelheim Int | FORMULATIONS INVOLVING A DPP4 INHIBITOR |
| BRPI0916997A2 (en) | 2008-08-06 | 2020-12-15 | Boehringer Ingelheim International Gmbh | DPP-4 INHIBITOR AND ITS USE |
| US20200155558A1 (en) | 2018-11-20 | 2020-05-21 | Boehringer Ingelheim International Gmbh | Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug |
| KR101004205B1 (en) | 2008-12-17 | 2010-12-24 | 동아제약주식회사 | The controlled released pharmaceutical compsitions of udenafil for sustained release property |
| AU2010212867B2 (en) | 2009-02-13 | 2013-05-16 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition comprising a SGLT2 inhibitor, a DPP-IV inhibitor and optionally a further antidiabetic agent and uses thereof |
| US9901551B2 (en) | 2009-04-20 | 2018-02-27 | Ambra Bioscience Llc | Chemosensory receptor ligand-based therapies |
| US8828953B2 (en) | 2009-04-20 | 2014-09-09 | NaZura BioHealth, Inc. | Chemosensory receptor ligand-based therapies |
| CA2758976C (en) | 2009-04-20 | 2015-02-03 | Alain Baron | Chemosensory receptor ligand-based therapies |
| EP3646859A1 (en) | 2009-11-27 | 2020-05-06 | Boehringer Ingelheim International GmbH | Treatment of genotyped diabetic patients with dpp-iv inhibitors such as linagliptin |
| US9198861B2 (en) | 2009-12-22 | 2015-12-01 | Mallinckrodt Llc | Methods of producing stabilized solid dosage pharmaceutical compositions containing morphinans |
| US20110150989A1 (en) * | 2009-12-22 | 2011-06-23 | Mallinkckrodt Inc. | Methods of Producing Stabilized Solid Dosage Pharmaceutical Compositions Containing Morphinans |
| AU2011249722B2 (en) | 2010-05-05 | 2015-09-17 | Boehringer Ingelheim International Gmbh | Combination therapy |
| ES2575860T3 (en) | 2010-07-09 | 2016-07-01 | Bhv Pharma, Inc. | Combined immediate / delayed release delivery system for short half-life pharmaceutical products that include remogliflozin |
| US9486463B2 (en) | 2010-10-19 | 2016-11-08 | Ambra Bioscience Llc | Chemosensory receptor ligand-based therapies |
| US9034883B2 (en) | 2010-11-15 | 2015-05-19 | Boehringer Ingelheim International Gmbh | Vasoprotective and cardioprotective antidiabetic therapy |
| KR20140035331A (en) | 2011-01-07 | 2014-03-21 | 엘셀릭스 테라퓨틱스 인코포레이티드 | Chemosensory receptor ligand-based therapies |
| CN102058555A (en) * | 2011-01-13 | 2011-05-18 | 北京汇诚瑞祥医药技术有限公司 | Doxazosin controlled release tablet |
| AR085689A1 (en) | 2011-03-07 | 2013-10-23 | Boehringer Ingelheim Int | PHARMACEUTICAL COMPOSITIONS OF METFORMIN, LINAGLIPTINE AND AN SGLT-2 INHIBITOR |
| CN102188431A (en) * | 2011-05-09 | 2011-09-21 | 浙江九旭药业有限公司 | Doxazosin mesylate sustained-release tablets and preparation method thereof |
| US8741885B1 (en) | 2011-05-17 | 2014-06-03 | Mallinckrodt Llc | Gastric retentive extended release pharmaceutical compositions |
| US8858963B1 (en) | 2011-05-17 | 2014-10-14 | Mallinckrodt Llc | Tamper resistant composition comprising hydrocodone and acetaminophen for rapid onset and extended duration of analgesia |
| US8658631B1 (en) | 2011-05-17 | 2014-02-25 | Mallinckrodt Llc | Combination composition comprising oxycodone and acetaminophen for rapid onset and extended duration of analgesia |
| US20130143867A1 (en) | 2011-12-02 | 2013-06-06 | Sychroneuron Inc. | Acamprosate formulations, methods of using the same, and combinations comprising the same |
| US9555001B2 (en) | 2012-03-07 | 2017-01-31 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition and uses thereof |
| WO2013158928A2 (en) | 2012-04-18 | 2013-10-24 | Elcelyx Therapeutics, Inc. | Chemosensory receptor ligand-based therapies |
| EP3685839A1 (en) | 2012-05-14 | 2020-07-29 | Boehringer Ingelheim International GmbH | Linagliptin for use in the treatment of albuminuria and kidney related diseases |
| WO2013174767A1 (en) | 2012-05-24 | 2013-11-28 | Boehringer Ingelheim International Gmbh | A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference |
| WO2014197744A1 (en) | 2013-06-05 | 2014-12-11 | Synchroneuron, Inc. | Acamprosate formulations, methods of using the same, and combinations comprising the same |
| ES2950384T3 (en) | 2014-02-28 | 2023-10-09 | Boehringer Ingelheim Int | Medical use of a DPP-4 inhibitor |
| CN105616378A (en) * | 2014-10-31 | 2016-06-01 | 康普药业股份有限公司 | Fluconazole capsule and preparation method therefor |
| BR112018072401A2 (en) | 2016-06-10 | 2019-02-19 | Boehringer Ingelheim International Gmbh | combinations of linagliptin and metformin |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IT1198386B (en) * | 1982-07-06 | 1988-12-21 | Lepetit Spa | A PROTRACTED RELEASE PRODUCT CONTAINING SULOCTIDYL |
| US4765989A (en) * | 1983-05-11 | 1988-08-23 | Alza Corporation | Osmotic device for administering certain drugs |
| US4837111A (en) * | 1988-03-21 | 1989-06-06 | Alza Corporation | Dosage form for dispensing drug for human therapy |
| IL92966A (en) * | 1989-01-12 | 1995-07-31 | Pfizer | Dispensing devices powered by hydrogel |
| ES2064117T3 (en) * | 1990-07-23 | 1995-01-16 | Alza Corp | ORAL OSMOTIC DEVICE FOR THE SUPPLY OF NICOTINE. |
-
1995
- 1995-11-21 GB GBGB9523752.5A patent/GB9523752D0/en active Pending
-
1996
- 1996-11-11 BR BR9611626A patent/BR9611626A/en not_active Application Discontinuation
- 1996-11-11 EP EP96938215A patent/EP0862437A1/en not_active Withdrawn
- 1996-11-11 NZ NZ322053A patent/NZ322053A/en unknown
- 1996-11-11 AU AU75721/96A patent/AU709560B2/en not_active Ceased
- 1996-11-11 KR KR1019980703777A patent/KR19990071505A/en not_active Application Discontinuation
- 1996-11-11 PL PL96326981A patent/PL326981A1/en unknown
- 1996-11-11 SK SK630-98A patent/SK63098A3/en unknown
- 1996-11-11 HU HU9903734A patent/HUP9903734A3/en unknown
- 1996-11-11 CA CA002232715A patent/CA2232715A1/en not_active Abandoned
- 1996-11-11 TR TR1998/00902T patent/TR199800902T2/en unknown
- 1996-11-11 WO PCT/EP1996/005020 patent/WO1997018814A1/en not_active Application Discontinuation
- 1996-11-11 CZ CZ981554A patent/CZ155498A3/en unknown
- 1996-11-11 CN CN96198486A patent/CN1215993A/en active Pending
- 1996-11-11 JP JP9519364A patent/JPH10513481A/en active Pending
- 1996-11-20 AR ARP960105252A patent/AR004335A1/en unknown
- 1996-11-20 PE PE1996000831A patent/PE22898A1/en not_active Application Discontinuation
- 1996-11-20 TN TNTNSN96141A patent/TNSN96141A1/en unknown
- 1996-11-20 MA MA24397A patent/MA26410A1/en unknown
- 1996-11-20 YU YU62096A patent/YU62096A/en unknown
- 1996-11-20 ZA ZA9609722A patent/ZA969722B/en unknown
- 1996-11-21 CO CO96061449A patent/CO4480020A1/en unknown
- 1996-11-21 HR HR9523752.5A patent/HRP960554A2/en not_active Application Discontinuation
- 1996-11-21 AP APAP/P/1996/000883A patent/AP718A/en active
-
1998
- 1998-03-31 IS IS4706A patent/IS4706A/en unknown
- 1998-05-08 BG BG102438A patent/BG102438A/en unknown
- 1998-05-19 OA OA9800058A patent/OA10687A/en unknown
- 1998-05-20 NO NO982302A patent/NO982302L/en not_active Application Discontinuation
- 1998-05-20 MX MX9804008A patent/MX9804008A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| TR199800902T2 (en) | 1998-09-21 |
| CN1215993A (en) | 1999-05-05 |
| PL326981A1 (en) | 1998-11-09 |
| NZ322053A (en) | 1999-11-29 |
| CZ155498A3 (en) | 1999-03-17 |
| YU62096A (en) | 1999-03-04 |
| CO4480020A1 (en) | 1997-07-09 |
| JPH10513481A (en) | 1998-12-22 |
| AR004335A1 (en) | 1998-11-04 |
| BG102438A (en) | 1999-01-29 |
| AU7572196A (en) | 1997-06-11 |
| HRP960554A2 (en) | 1998-02-28 |
| HUP9903734A2 (en) | 2000-03-28 |
| EP0862437A1 (en) | 1998-09-09 |
| MX9804008A (en) | 1998-09-30 |
| OA10687A (en) | 2002-11-27 |
| AU709560B2 (en) | 1999-09-02 |
| MA26410A1 (en) | 2004-12-20 |
| BR9611626A (en) | 1999-06-01 |
| CA2232715A1 (en) | 1997-05-29 |
| GB9523752D0 (en) | 1996-01-24 |
| NO982302L (en) | 1998-07-17 |
| WO1997018814A1 (en) | 1997-05-29 |
| IS4706A (en) | 1998-03-31 |
| HUP9903734A3 (en) | 2000-04-28 |
| TNSN96141A1 (en) | 2005-03-15 |
| AP9600883A0 (en) | 1997-01-31 |
| AP718A (en) | 1999-01-06 |
| NO982302D0 (en) | 1998-05-20 |
| SK63098A3 (en) | 1999-05-07 |
| KR19990071505A (en) | 1999-09-27 |
| PE22898A1 (en) | 1998-05-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA967745B (en) | Pharmaceutical formulations. | |
| ZA969722B (en) | Pharmaceutical formulations. | |
| ZA967034B (en) | Pharmaceutical compositions. | |
| ZA965190B (en) | Pharmaceutical composition. | |
| ZA962338B (en) | Oral 2-methyl-thieno-benzodiazepine formulation. | |
| GB9408117D0 (en) | Pharmaceutical formulations | |
| HU9603495D0 (en) | 1-phenyl-2-dimethylaminomethyl-cyclohexan-1-ol-compounds, as pharmaceutical agents | |
| GB9519363D0 (en) | Pharmaceutical formulation | |
| ZA969176B (en) | Stable freeze-dried pharmaceutical formulation. | |
| ZA967546B (en) | Pharmaceutical formulation. | |
| ZA951781B (en) | Pharmaceutical formulations | |
| ZA968081B (en) | Pharmaceutical composition. | |
| GB9523566D0 (en) | Pharmaceutical formulation | |
| ZA9610589B (en) | Pharmaceutical compounds. | |
| ZA96392B (en) | Pharmaceutical formulations | |
| GB9413542D0 (en) | Pharmaceutical formulations | |
| GB9500978D0 (en) | Pharmaceutical formulations | |
| ZA957349B (en) | Pharmaceutical formulations. | |
| ZA972387B (en) | Pharmaceutical formulations. | |
| GB9516584D0 (en) | Pharmaceutical formulations | |
| GB9503752D0 (en) | Pharmaceutical formulations | |
| GB9508989D0 (en) | Pharmaceutical formulations | |
| ZA968757B (en) | Novel formulations. | |
| ZA9710675B (en) | Pharmaceutical formulation. | |
| ZA976795B (en) | Pharmaceutical formulation. |